

Richard A Larson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1997019/richard-a-larson-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

532
papers

61,330
citations

110
h-index

242
g-index

566
ext. papers

69,236
ext. citations

6.3
avg, IF

6.95
L-index

#	Paper	IF	Citations
532	Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.. <i>Blood</i> , 2022 ,	2.2	3
531	Obesity in children with acute promyelocytic leukemia: What is its prevalence and prognostic significance?. <i>Pediatric Blood and Cancer</i> , 2022 , e29613	3	
530	Acute Lymphoblastic Leukemia: Clinical Presentation, Diagnosis, and Classification. <i>Hematologic Malignancies</i> , 2021 , 157-167	0	
529	Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data. <i>Blood</i> , 2021 , 138, 337-337	2.2	
528	High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance). <i>Blood</i> , 2021 , 138, 221-221	2.2	0
527	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. <i>Blood</i> , 2021 , 138, 639-639	2.2	2
526	Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance). <i>Blood</i> , 2021 , 138, 226-226	2.2	
525	White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance). <i>Blood</i> , 2021 , 138, 3369-3369	2.2	0
524	Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL). <i>Blood</i> , 2021 , 138, 1746-1746	2.2	0
523	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. <i>Nature Communications</i> , 2021 , 12, 6233	17.4	2
522	Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. <i>Leukemia Research</i> , 2021 , 111, 106736	2.7	0
521	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021 , 35, 2076-2085	10.7	10
520	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021 , 35, 2539-2551	10.7	15
519	Economics influences therapy decisions in chronic myeloid leukaemia: should it?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 3693-3698	4.9	0
518	Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. <i>EJHaem</i> , 2021 , 2, 413-420	0.9	
517	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. <i>Blood</i> , 2021 , 137, 3093-3104	2.2	19
516	Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 42-50	13.4	16

515	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021 , 5, 504-512	7.8	9
514	Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. <i>Leukemia</i> , 2021 , 35, 440-453	10.7	36
513	Pharmacoeconomic Considerations for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia. <i>Hematologic Malignancies</i> , 2021 , 93-104	0	
512	Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. <i>Leukemia</i> , 2021 , 35, 2220-2231	10.7	5
511	Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. <i>Blood Cancer Journal</i> , 2021 , 11, 39	7	4
510	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , 2021 , 35, 2854-2861	10.7	2
509	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , 2021 ,	10.7	4
508	Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). <i>Blood Advances</i> , 2021 , 5, 2775-2787	7.8	3
507	Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy. <i>Blood Advances</i> , 2021 , 5, 4140-4148	7.8	0
506	Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. <i>Blood Advances</i> , 2021 , 5, 4691-4700	7.8	1
505	Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. <i>European Journal of Cancer</i> , 2021 , 157, 428-440	7.5	4
504	Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2204-2206	4.4	1
503	Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1161-1168	4.4	5
502	Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. <i>JCO Oncology Practice</i> , 2020 , 16, e464-e475	2.3	4
501	Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force. <i>Journal of Geriatric Oncology</i> , 2020 , 11, 1199-1209	3.6	7
500	Therapy-Related Myeloid Neoplasms in 108 Patients Following Radiation Therapy Only. <i>Blood</i> , 2020 , 136, 25-26	2.2	
499	Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT). <i>Blood</i> , 2020 , 136, 39-40	2.2	
498	Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL). <i>Blood</i> , 2020 , 136, 7-8	2.2	5

497	Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results. <i>Blood</i> , 2020 , 136, 41-42	2.2	1
496	Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). <i>Journal of Geriatric Oncology</i> , 2020 , 11, 107-113	3.6	25
495	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020 , 4, 4945-4954	7.8	13
494	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020 , 135, 371-380	2.2	53
493	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. <i>Blood Advances</i> , 2020 , 4, 696-705	7.8	21
492	A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. <i>Blood Advances</i> , 2020 , 4, 599-606	7.8	2
491	Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML. <i>New England Journal of Medicine</i> , 2019 , 381, 1728-1740	59.2	413
490	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2113-2123	4.7	38
489	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. <i>Leukemia</i> , 2019 , 33, 2599-2609	10.7	36
488	Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. <i>Experimental Hematology and Oncology</i> , 2019 , 8, 1	7.8	9
487	Patients' perspectives on the definition of cure in chronic myeloid leukemia. <i>Leukemia Research</i> , 2019 , 80, 40-42	2.7	1
486	Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019 , 60, 629-638	1.9	1
485	Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. <i>Cancer</i> , 2019 , 125, 4181-4192	6.4	46
484	Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?. <i>Best Practice and Research in Clinical Haematology</i> , 2019 , 32, 101102	4.2	4
483	Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors. <i>Blood</i> , 2019 , 134, 4176-4176	2.2	3
482	Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019 , 134, 1956-1956	2.2	2
481	Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication. <i>Blood</i> , 2019 , 134, 475-475	2.2	2
480	Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10103 to Patients Reported to the CIBMTR. <i>Blood</i> , 2019 , 134, 261-261	2.2	5

479	Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis. <i>Blood</i> , 2019 , 134, 2924-2924	2.2	20
478	Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS. <i>Blood</i> , 2019 , 134, 3324-3324	2.2	
477	Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2019 , 134, 705-705	2.2	1
476	Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). <i>Blood Advances</i> , 2019 , 3, 1714-1721	7.8	6
475	Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. <i>Blood Advances</i> , 2019 , 3, 3488-3498	7.8	31
474	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. <i>Blood Advances</i> , 2019 , 3, 4228-4237	7.8	16
473	Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). <i>Pediatric Blood and Cancer</i> , 2019 , 66, e27542	3	6
472	A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. <i>Blood</i> , 2019 , 133, 1548-1559	2.2	178
471	Pepsi or Coke? Influence of acid on dasatinib absorption. <i>Journal of Oncology Pharmacy Practice</i> , 2018 , 24, 156-158	1.7	7
470	Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1007-1014	4.7	12
469	Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. <i>BMC Cancer</i> , 2018 , 18, 359	4.8	11
468	Therapy-Related Acute Promyelocytic Leukemia 2018 , 231-242		
467	RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. <i>Nature Communications</i> , 2018 , 9, 1163	17.4	73
466	Managing CNS disease in adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 3-13	1.9	32
465	A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 4	22.4	40
464	WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. <i>Experimental Hematology and Oncology</i> , 2018 , 7, 1	7.8	15
463	FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018 , 132, 2800-2800	2.2	4
462	Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603). <i>Blood</i> , 2018 , 132, 1534-1534	2.2	1

461	Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603). <i>Blood</i> , 2018 , 132, 435-435	2.2	3
460	Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. <i>Blood</i> , 2018 , 132, 1386-1386	2.2	13
459	Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614). <i>Blood</i> , 2018 , 132, 1386-1386	2.2	
458	ABL Tyrosine Kinase Inhibitors (TKIs) Are Associated with Increased Rho-Associated Kinase (ROCK) Activity That May Contribute to Vascular Toxicity in Patients with Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2018 , 132, 1739-1739	2.2	0
457	Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study. <i>Blood</i> , 2018 , 132, 2170-2170	2.2	
456	Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey. <i>Blood</i> , 2018 , 132, 5843-5843	2.2	
455	Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018 , 132, 4073-4073	2.2	23
454	Treatment of Acute Promyelocytic Leukemia in Adults. <i>Journal of Oncology Practice</i> , 2018 , 14, 649-657	3.1	28
453	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018 , 379, 2517-2528	59.2	455
452	Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. <i>Blood Advances</i> , 2018 , 2, 444-453	7.8	88
451	Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). <i>Blood Advances</i> , 2018 , 2, 1705-1718	7.8	9
450	Imatinib is still recommended for frontline therapy for CML. <i>Blood Advances</i> , 2018 , 2, 3648-3652	7.8	12
449	Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. <i>Blood Advances</i> , 2018 , 2, 1522-1531	7.8	23
448	Randomized trial of 10 days of decitabine + bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). <i>Blood Advances</i> , 2018 , 2, 3608-3617	7.8	20
447	Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. <i>Pharmacogenomics Journal</i> , 2017 , 17, 274-279	3.5	24
446	Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1-7	1.9	14
445	Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2017 , 376, 917-927	59.2	618
444	Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. <i>Blood</i> , 2017 , 129, 1763-1767	2.2	55

443	Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. <i>British Journal of Haematology</i> , 2017 , 178, 906-913	4.5	28
442	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. <i>Lancet Oncology</i> , 2017 , 18, 1061-1075	21.7	305
441	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. <i>New England Journal of Medicine</i> , 2017 , 377, 454-464	59.2	1067
440	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017 , 129, 424-447	2.2	2764
439	FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N-Methyladenosine RNA Demethylase. <i>Cancer Cell</i> , 2017 , 31, 127-141	24.3	736
438	Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. <i>Haematologica</i> , 2017 , 102, 519-528	6.6	16
437	Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). <i>Leukemia</i> , 2017 , 31, 34-39	10.7	48
436	A phase 2 study incorporating sorafenib into the chemotherapy for older adults with -mutated acute myeloid leukemia: CALGB 11001. <i>Blood Advances</i> , 2017 , 1, 331-340	7.8	42
435	Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2100-2103	4.7	31
434	Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia. <i>Acta Haematologica</i> , 2016 , 136, 210-218	2.7	13
433	Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the USA and the EU. <i>Hematologic Malignancies</i> , 2016 , 231-255	0	
432	miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. <i>Nature Communications</i> , 2016 , 7, 11452	17.4	89
431	Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. <i>Cancer</i> , 2016 , 122, 304-11	6.4	89
430	Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. <i>Cancer</i> , 2016 , 122, 2178-85	6.4	59
429	Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. <i>Cancer Research</i> , 2016 , 76, 4470-80	10.1	38
428	Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1065-1072	4.7	14
427	Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1807-13	1.9	5
426	Positron Emission Tomography-Computed Tomography Imaging of a Patient With Several Myeloid Sarcomas With FLT3-ITD and NPM1 Mutations. <i>Journal of Clinical Oncology</i> , 2016 , 34, e123-5	2.2	1

425	Dasatinib-Related Pulmonary Toxicity Mimicking an Atypical Infection. <i>Journal of Clinical Oncology</i> , 2016 , 34, e46-8	2.2	5
424	Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2298-306	1.9	31
423	Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. <i>Leukemia</i> , 2016 , 30, 1044-54	10.7	497
422	Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	66
421	Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 214-214	2.2	0
420	Fto Plays an Oncogenic Role in Acute Myeloid Leukemia As a N6-Methyladenosine RNA Demethylase. <i>Blood</i> , 2016 , 128, 2706-2706	2.2	3
419	WT1 Peptide Vaccine Is Able to Induce WT1-Specific Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 3984-3984	2.2	1
418	SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016 , 128, 901-901	2.2	33
417	Evaluation of a pre-transplant serum biomarker score for allogeneic hematopoietic stem cell transplant (HCT) and association with clinical factors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e18537-e18537	2.2	3
416	Comorbidity from Solid Tumor or Hematologic Malignancy Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) May Both Increase Non-Relapse Mortality. <i>Blood</i> , 2016 , 128, 5844-5844	2.2	
415	Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. <i>American Journal of Hematology</i> , 2016 , 91, 199-204	7.1	34
414	Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. <i>Leukemia</i> , 2016 , 30, 1672-81	10.7	65
413	Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. <i>Haematologica</i> , 2016 , 101, 634-43	6.6	26
412	A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. <i>Investigational New Drugs</i> , 2015 , 33, 371-9	4.3	8
411	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 996-1000	6.4	105
410	Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2015 , 39, 495-500	2.7	41
409	Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 443-9	2	28
408	Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. <i>Annals of Hematology</i> , 2015 , 94 Suppl 2, S249-57	3	34

407	Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma. <i>Leukemia</i> , 2015 , 29, 2113-6	10.7	31
406	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4167-75	2.2	111
405	miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with ibrutinib. <i>Leukemia</i> , 2015 , 29, 1210-3	10.7	15
404	Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 559-64	4.7	42
403	Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. <i>Leukemia</i> , 2015 , 29, 567-75	10.7	54
402	Is there a best TKI for chronic phase CML?. <i>Hematology American Society of Hematology Education Program</i> , 2015 , 2015, 250-6	3.1	4
401	Overexpression and knockout of miR-126 both promote leukemogenesis. <i>Blood</i> , 2015 , 126, 2005-15	2.2	50
400	Is there a best TKI for chronic phase CML?. <i>Blood</i> , 2015 , 126, 2370-5	2.2	36
399	Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. <i>British Journal of Haematology</i> , 2015 , 171, 373-7	4.5	10
398	Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. <i>Leukemia</i> , 2015 , 29, 2031-7	1.9	7
397	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2015 , 16, 57-66	21.7	832
396	Targeted Treatment of FLT3 -Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides. <i>Blood</i> , 2015 , 126, 3784-3784	2.2	1
395	Efficacy of Single-Agent Decitabine in Relapsed and Primary Refractory (rel/ref) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015 , 126, 2518-2518	2.2	
394	Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015 , 126, 3777-3777 ^{2.2}	2.2	
393	Overexpression and Knockout of Mir-126 Both Promote Leukemogenesis through Targeting Distinct Gene Signaling. <i>Blood</i> , 2015 , 126, 3667-3667	2.2	0
392	The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment. <i>Annals of the New York Academy of Sciences</i> , 2014 , 1310, 7-31	6.5	40
391	Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10002. <i>British Journal of Haematology</i> , 2014 , 165, 102-11	4.5	68
390	BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. <i>Cancer Cell</i> , 2014 , 26, 428-442	24.3	233

389	Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. <i>Clinical Cancer Research</i> , 2014 , 20, 490-8	12.9	82
388	Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. <i>British Journal of Haematology</i> , 2014 , 165, 497-503	4.5	31
387	Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays. <i>Leukemia Research</i> , 2014 , 38, 1091-6	2.7	15
386	Geriatric Assessment (GA) to Predict Survival in Older Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, S39-S40	4.7	3
385	Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. <i>Haematologica</i> , 2014 , 99, 1204-11	6.6	38
384	Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. <i>Haematologica</i> , 2014 , 99, 1373-9	6.6	157
383	Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. <i>Blood</i> , 2014 , 123, 1353-60	2.2	196
382	Management of Therapy-Related Myeloid Neoplasms 2014 , 120-125		
381	Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 927-38	3.5	16
380	Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). <i>Haematologica</i> , 2014 , 99, 111-5	6.6	73
379	Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. <i>Haematologica</i> , 2014 , 99, 308-13	6.6	28
378	Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1523-32	1.9	41
377	The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q). <i>British Journal of Haematology</i> , 2014 , 166, 550-6	4.5	26
376	Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2014 , 164, 223-32	4.5	46
375	Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. <i>Cancer</i> , 2014 , 120, 1010-7	6.4	21
374	Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 1005-13	3.8	5
373	Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. <i>Leukemia Research</i> , 2014 , 38, 329-33	2.7	20
372	Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study. <i>Blood</i> , 2014 , 124, 1093-1093	2.2	4

371	Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd. <i>Blood</i> , 2014 , 124, 4541-4541	2.2	30
370	What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?. <i>Blood</i> , 2014 , 124, 738-738	2.2	5
369	Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403. <i>Blood</i> , 2014 , 124, 796-796	2.2	72
368	Frequency and Risk Factors of Cord Graft Failure (CGF) Following Reduced Intensity Conditioning Haplo-Cord Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014 , 124, 2463-2463	2.2	
367	Incidence and Predictors of Respiratory Viral Infections By Multi-Plex PCR in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients 50 Years and Older Including Geriatric Assessment (GA). <i>Blood</i> , 2014 , 124, 2464-2464	2.2	
366	The Outcomes of Second Allogeneic Stem Cell Transplantation for Disease Relapse after T Cell Depleted Allogeneic Stem Cell Transplantation: A Single Center Experience-University of Chicago. <i>Blood</i> , 2014 , 124, 2509-2509	2.2	2
365	Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. <i>Cancer</i> , 2013 , 119, 90-8	6.4	85
364	A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2013 , 48, 1437-43	4.4	18
363	Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1172-81	2.2	112
362	Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia. <i>Leukemia</i> , 2013 , 27, 1411-3	10.7	40
361	Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. <i>Cancer</i> , 2013 , 119, 4170-9	6.4	31
360	Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. <i>Leukemia</i> , 2013 , 27, 107-12	10.7	169
359	The evolving challenge of therapy-related myeloid neoplasms. <i>Best Practice and Research in Clinical Haematology</i> , 2013 , 26, 309-17	4.2	56
358	Current practices in the management of chronic myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 48-54	2	8
357	Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. <i>Leukemia</i> , 2013 , 27, 907-13	10.7	22
356	Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2654-9	1.9	6
355	Immune reconstitution after combined haploidentical and umbilical cord blood transplant. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1242-9	1.9	20
354	Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. <i>Journal of Clinical Oncology</i> , 2013 , 31, 923-9	2.2	86

353	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , 2013 , 122, 872-84	2.2	1413
352	A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). <i>Investigational New Drugs</i> , 2013 , 31, 1311-20	4.3	14
351	The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). <i>Leukemia and Lymphoma</i> , 2013 , 54, 252-4	1.9	30
350	Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Myeloid Leukemia following Orthotopic Cardiac Transplantation. <i>Case Reports in Hematology</i> , 2013 , 2013, 140138	0.7	1
349	miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 11511-6	11.5	86
348	Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. <i>Journal of Clinical Oncology</i> , 2013 , 31, 440-7	2.2	50
347	A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. <i>Blood</i> , 2013 , 121, 4854-60	2.2	441
346	Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. <i>Blood</i> , 2013 , 121, 3703-8	2.2	73
345	inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFβ-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. <i>Blood</i> , 2013 , 121, 385-91	2.2	34
344	DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML. <i>Blood</i> , 2013 , 122, 1548-1548	2.2	1
343	A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2012 , 120, 3898-905	2.2	132
342	Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. <i>Cancer Cell</i> , 2012 , 22, 524-35	24.3	132
341	High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). <i>Leukemia and Lymphoma</i> , 2012 , 53, 445-50	1.9	16
340	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. <i>Blood</i> , 2012 , 119, 2314-24	2.2	128
339	The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 18-36.e6	4.7	53
338	The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 16-7	4.7	18
337	Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 913-21	4.7	31
336	Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4515-23	2.2	310

335	A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. <i>Journal of Hematology and Oncology</i> , 2012 , 5, 71	22.4	52
334	Influence of related donor age on outcomes after peripheral blood stem cell transplantation. <i>Cytotherapy</i> , 2012 , 14, 707-15	4.8	12
333	Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 345-50	3.5	20
332	Author reply to Fujimi et al. <i>European Journal of Clinical Pharmacology</i> , 2012 , 68, 1573-1574	2.8	
331	Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1743-8	1.9	14
330	The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia. <i>Leukemia</i> , 2012 , 26, 1713-7	10.7	16
329	miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2012 , 120, 249-58	2.2	58
328	RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3109-18	2.2	195
327	Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 742-50	2.2	215
326	FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2012 , 59, 662-7	3	38
325	Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. <i>Leukemia</i> , 2012 , 26, 2197-203	10.7	335
324	Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2483-91	2.2	100
323	Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. <i>European Journal of Clinical Pharmacology</i> , 2012 , 68, 723-33	2.8	74
322	Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. <i>Leukemia</i> , 2012 , 26, 959-62	10.7	63
321	Gemtuzumab ozogamicin: time to resurrect?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3921-3	2.2	84
320	Treatment-influenced associations of PML-RAR α mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. <i>Blood</i> , 2012 , 120, 2098-108	2.2	46
319	MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 19397-402	11.5	101
318	Amelanocytic anhidrotic alopecia areata-like phenotype after allogeneic hematopoietic cell transplant. <i>Archives of Dermatology</i> , 2012 , 148, 931-4		5

317	Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). <i>Blood</i> , 2012 , 120, 167-167	2.2	10
316	Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd. <i>Blood</i> , 2012 , 120, 1686-1686	2.2	10
315	A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502. <i>Blood</i> , 2012 , 120, 230-230	2.2	10
314	Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2012 , 120, 3535-3535	2.2	1
313	Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance). <i>Blood</i> , 2012 , 120, 44-44	2.2	2
312	R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission. <i>Blood</i> , 2012 , 120, 676-676	2.2	1
311	Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy. <i>Translational Pediatrics</i> , 2012 , 1, 120-2	4.2	7
310	Blockade of Mir-150 Maturation by MLL-Fusion/MYC/Lin-28 Is Required for MLL-Associated Leukemia. <i>Blood</i> , 2012 , 120, 3499-3499	2.2	0
309	Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. <i>Blood</i> , 2011 , 118, 6438-45	2.2	137
308	Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1796-803	4.7	108
307	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. <i>Lancet Oncology, The</i> , 2011 , 12, 841-51	21.7	383
306	TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1373-81	2.2	266
305	Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Haematologica</i> , 2011 , 96, 1488-95	6.6	19
304	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. <i>Blood</i> , 2011 , 117, 1141-5	2.2	296
303	Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. <i>Blood</i> , 2011 , 117, 7007-13	2.2	54
302	Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. <i>Blood</i> , 2011 , 118, 3525-7	2.2	41
301	Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2011 , 118, 4188-98	2.2	48
300	ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. <i>Blood</i> , 2011 , 118, 6920-9	2.2	216

299	CML: live long and prosper. <i>Blood</i> , 2011 , 118, 4499-500	2.2	4
298	An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. <i>Seminars in Oncology</i> , 2011 , 38, 215-24	5.5	16
297	Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?. <i>Seminars in Oncology</i> , 2011 , 38, 196-214	5.5	19
296	High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. <i>Leukemia Research</i> , 2011 , 35, 329-33	2.7	24
295	Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1349-55	2.2	113
294	Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. <i>Leukemia</i> , 2011 , 25, 800-7	10.7	22
293	Genetic pathways leading to therapy-related myeloid neoplasms. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011 , 3, e2011019	3.2	12
292	Prognosis and therapy when acute promyelocytic leukemia and other "good risk" acute myeloid leukemias occur as a therapy-related myeloid neoplasm. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011 , 3, e2011032	3.2	25
291	Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID. <i>Blood</i> , 2011 , 118, 114-114	2.2	2
290	Prognostic Significance of Karyotype in Octogenarian Patients (Pts) with Acute Myeloid Leukemia (AML) An International Study. <i>Blood</i> , 2011 , 118, 2521-2521	2.2	1
289	Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710. <i>Blood</i> , 2011 , 118, 258-258	2.2	5
288	Update of An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2011 , 118, 2772-2772	2.2	5
287	Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies. <i>Blood</i> , 2011 , 118, 289-289	2.2	2
286	Therapy-Related Myeloid Neoplasms (t-MN) in 71 Patients Following Radiation Therapy (RT) Only. <i>Blood</i> , 2011 , 118, 3522-3522	2.2	0
285	Treatment of Acute Lymphoblastic Leukemia in Middle-Age and Older Adults 2011 , 115-126		
284	Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study. <i>Blood</i> , 2011 , 118, 1948-1948	2.2	
283	Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001. <i>Blood</i> , 2011 , 118, 2541-2541	2.2	
282	Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies. <i>Blood</i> , 2011 , 118, 830-830	2.2	0

281	Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials.. <i>Blood</i> , 2011 , 118, 1791-1791	2.2	
280	Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia. <i>Blood</i> , 2011 , 118, 236-236	2.2	
279	A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes. <i>Blood</i> , 2011 , 118, 496-496	2.2	
278	MiR-3151, a Novel MicroRNA Embedded in BAALC, Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). <i>Blood</i> , 2011 , 118, 1462-1462	2.2	
277	Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. <i>Leukemia</i> , 2010 , 24, 1299-301	10.7	80
276	Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4500-6	2.2	64
275	Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5257-64	2.2	155
274	IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2348-55	2.2	599
273	Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. <i>Leukemia and Lymphoma</i> , 2010 , 51, 2240-9	1.9	28
272	Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. <i>Journal of Biological Chemistry</i> , 2010 , 285, 32596-605 ⁴	5.4	35
271	Therapy-related myeloid sarcoma with an NPM1 mutation. <i>Leukemia and Lymphoma</i> , 2010 , 51, 2130-1	1.9	4
270	Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 437-44	2.2	154
269	BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Blood</i> , 2010 , 116, 5660-9	2.2	99
268	Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 596-604	2.2	268
267	Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2010 , 51, 995-1006	1.9	14
266	P-glycoprotein inhibition using valsopodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. <i>Blood</i> , 2010 , 116, 1413-21	2.2	98
265	Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Blood</i> , 2010 , 116, 788-92	2.2	71
264	Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. <i>Blood</i> , 2010 , 116, 3751-7	2.2	297

263	Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). <i>Blood</i> , 2010 , 116, 3758-65	2.2	382
262	FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Blood</i> , 2010 , 116, 3622-6	2.2	179
261	Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. <i>Blood</i> , 2010 , 116, 2420-8	2.2	62
260	Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. <i>Blood</i> , 2010 , 116, 5650-9	2.2	29
259	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010 , 115, 453-74	2.2	2483
258	Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. <i>New England Journal of Medicine</i> , 2010 , 362, 2251-9	59.2	1266
257	Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia. <i>Chemico-Biological Interactions</i> , 2010 , 184, 21-5	5	9
256	Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. <i>Chemico-Biological Interactions</i> , 2010 , 184, 50-7	5	63
255	Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. <i>American Journal of Hematology</i> , 2010 , 85, 164-70	7.1	67
254	Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd. <i>Blood</i> , 2010 , 116, 2291-2291	2.2	9
253	Pre-Donor Evaluation of an HLA Matched Sibling Identifies a Novel Inherited RUNX1 Mutation Encoding a Missense Mutation Found Outside of the RUNT Domain in Familial Platelet Disorder. <i>Blood</i> , 2010 , 116, 2709-2709	2.2	7
252	Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3472-9	2.2	154
251	Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1809-17	1.9	47
250	High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2009 , 114, 647-50	2.2	348
249	Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1589-96	1.9	24
248	Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3198-204	2.2	135
247	Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). <i>Cancer</i> , 2009 , 115, 84-93	6.4	6
246	Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2009 , 115, 551-60	6.4	97

245	A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 859-64	3.5	29
244	Auto-SCT for AML in second remission: CALGB study 9620. <i>Bone Marrow Transplantation</i> , 2009 , 44, 353-9	4.4	27
243	Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6041-51	2.2	1019
242	Allogeneic hematopoietic cell transplantation is not recommended for all adults with standard-risk acute lymphoblastic leukemia in first complete remission. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 11-6	4.7	9
241	Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. <i>Journal of Hematology and Oncology</i> , 2009 , 2, 20	22.4	40
240	Discontinuing imatinib in chronic myeloid leukemia: don't try this at home. <i>Leukemia and Lymphoma</i> , 2009 , 50, 868-70	1.9	1
239	Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2009 , 50, 85-91	1.9	10
238	Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. <i>Leukemia</i> , 2009 , 23, 1054-61	10.7	711
237	Role of allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia. <i>Current Opinion in Oncology</i> , 2009 , 21, 601-8	4.2	4
236	Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. <i>Blood</i> , 2009 , 113, 5575-82	2.2	80
235	High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. <i>Haematologica</i> , 2009 , 94, 1669-75	6.6	39
234	Therapy-related myeloid neoplasms. <i>Haematologica</i> , 2009 , 94, 454-9	6.6	47
233	International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.. <i>Blood</i> , 2009 , 114, 1126-1126	2.2	252
232	Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study.. <i>Blood</i> , 2009 , 114, 1579-1579	2.2	1
231	Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2009 , 114, 536-536	2.2	15
230	Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously	2.2	94
229	Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. <i>Leukemia</i> , 2008 , 22, 1200-6	10.7	311
228	Allogeneic hematopoietic cell transplantation for adults with ALL. <i>Bone Marrow Transplantation</i> , 2008 , 42 Suppl 1, S18-S24	4.4	8

227	Rates of cholesterol biosynthesis are related to early differentiation in acute non-lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2008 , 54, 459-466	4.5	
226	Therapy-related myeloid leukemia. <i>Seminars in Oncology</i> , 2008 , 35, 418-29	5.5	212
225	Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 1209-16	4.7	69
224	Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. <i>Blood</i> , 2008 , 111, 4022-8	2.2	488
223	Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 15535-40	11.5	375
222	Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. <i>Clinical Cancer Research</i> , 2008 , 14, 7095-101	12.9	60
221	Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4934-9	2.2	97
220	MicroRNA expression in cytogenetically normal acute myeloid leukemia. <i>New England Journal of Medicine</i> , 2008 , 358, 1919-28	59.2	386
219	WilmsTumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4595-602	2.2	200
218	Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4603-9 ²		117
217	Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5078-87	2.2	266
216	Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. <i>Leukemia and Lymphoma</i> , 2008 , 49, 531-7	1.9	7
215	Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1274-8	1.9	10
214	What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. <i>Blood</i> , 2008 , 112, 1646-54	2.2	408
213	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. <i>Blood</i> , 2008 , 111, 1834-9	2.2	255
212	FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. <i>Blood</i> , 2008 , 111, 1552-9	2.2	221
211	High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. <i>Blood</i> , 2008 , 111, 5371-9	2.2	159
210	MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. <i>Blood</i> , 2008 , 112, 741-9	2.2	85

209	An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2008 , 112, 4193-201	2.2	281
208	Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. <i>Investigational New Drugs</i> , 2008 , 26, 233-9	4.3	44
207	A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. <i>Investigational New Drugs</i> , 2008 , 26, 331-8	4.3	11
206	Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis. <i>Blood</i> , 2008 , 112, 2809-2809	2.2	15
205	Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors. <i>Blood</i> , 2008 , 112, 3015-3015	2.2	1
204	Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study.. <i>Blood</i> , 2008 , 112, 3238-3238	2.2	22
203	Recent Clinical Trials in Acute Lymphoblastic Leukemia by the Cancer and Leukemia Group B 2008 , 137-144		2
202	Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. <i>Blood</i> , 2007 , 109, 4164-7	2.2	145
201	Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. <i>Blood</i> , 2007 , 109, 4143-50 ²		321
200	Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2007 , 20, 29-37	4.2	60
199	Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2007 , 40, 1027-32	4.4	67
198	Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine. <i>Seminars in Oncology</i> , 2007 , 34, S13-20	5.5	25
197	MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 19971-6	11.5	378
196	Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. <i>American Journal of Clinical Pathology</i> , 2007 , 127, 197-205	1.9	73
195	Etiology and management of therapy-related myeloid leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2007 , 2007, 453-9	3.1	65
194	Cardiac tamponade in a patient with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007 , 48, 829-32	1.9	2
193	High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3337-43	2.2	165
192	Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. <i>Journal of Clinical Oncology</i> , 2007 , 25, 793-8	2.2	340

191	End points to establish the efficacy of new agents in the treatment of acute leukemia. <i>Blood</i> , 2007 , 109, 1810-6	2.2	74
190	Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. <i>Blood</i> , 2007 , 109, 5164-7	2.2	85
189	Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. <i>Blood</i> , 2007 , 110, 2309-15	2.2	316
188	Chronic lymphocytic leukemia masquerading as uveitis. <i>Retina</i> , 2007 , 27, 1311-2	3.6	4
187	Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. <i>Blood</i> , 2007 , 109, 5136-42	2.2	226
186	Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. <i>Journal of Clinical Oncology</i> , 2007 , 25, 799-804	2.2	296
185	Successful allogeneic transplantation of patients with suspected prior invasive mold infection. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1799-805	1.9	13
184	Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808.. <i>Blood</i> , 2007 , 110, 157-157	2.2	16
183	IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.. <i>Blood</i> , 2007 , 110, 25-25	2.2	27
182	Nilotinib in Patients (pts) with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib.. <i>Blood</i> , 2007 , 110, 2815-2815	2.2	7
181	Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901).. <i>Blood</i> , 2007 , 110, 756-756	2.2	9
180	Genomic Rearrangements Associated with -5/del(5q) and -7/del(7q) in Myeloid Leukemias.. <i>Blood</i> , 2007 , 110, 1813-1813	2.2	1
179	MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations.. <i>Blood</i> , 2007 , 110, 3181-3181	2.2	
178	Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 57, 199-206	3.5	23
177	Phase III study of PSC-833 (valsopodar) in combination with vincristine, doxorubicin, and dexamethasone (valsopodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. <i>Cancer</i> , 2006 , 106, 830-8	6.4	100
176	Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3895-903	2.2	470
175	Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B. <i>Clinical Cancer Research</i> , 2006 , 12, 3556s-63s	12.9	10
174	Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 1030-5	11.5	31

173	Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3904-11	2.2	534
172	Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. <i>New England Journal of Medicine</i> , 2006 , 355, 2408-17	59.2	2811
171	Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. <i>Journal of Clinical Oncology</i> , 2006 , 24, 437-43	2.2	212
170	Management of acute lymphoblastic leukemia in older patients. <i>Seminars in Hematology</i> , 2006 , 43, 126-33	4	48
169	Nelarabine in the treatment of refractory T-cell malignant diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 1791-9	4	4
168	Myelodysplasia: when to treat and how. <i>Best Practice and Research in Clinical Haematology</i> , 2006 , 19, 293-300	4.2	8
167	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2006 , 108, 1809-20	2.2	998
166	The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 1-30	4.7	101
165	Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 954-64	4.7	108
164	Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. <i>Blood</i> , 2006 , 108, 1478-84	2.2	189
163	Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. <i>Blood</i> , 2006 , 108, 63-73	2.2	253
162	Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. <i>Blood</i> , 2006 , 108, 1677-83	2.2	108
161	Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples 2006 , 28, 1099		4
160	Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. <i>Bone Marrow Transplantation</i> , 2006 , 37, 307-10	4.4	41
159	A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare poor prognosis myeloid malignancies. <i>Leukemia</i> , 2006 , 20, 1295-7	10.7	91
158	CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights.. <i>Blood</i> , 2006 , 108, 2293-2293	2.2	2
157	Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib - An Analysis of IRIS Study Data.. <i>Blood</i> , 2006 , 108, 429-429	2.2	8
156	Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301.. <i>Blood</i> , 2006 , 108, 797-797	2.2	15

155	Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies.. <i>Blood</i> , 2006 , 108, 1952-1952	2.2	
154	New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).. <i>Blood</i> , 2006 , 108, 3675-3675	2.2	
153	Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. <i>International Journal of Oncology</i> , 2006 , 28, 1099-103 ¹		9
152	Acute lymphoblastic leukemia: older patients and newer drugs. <i>Hematology American Society of Hematology Education Program</i> , 2005 , 2005, 131-6	3.1	24
151	Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3404-11	2.2	133
150	The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 823-61	4.7	58
149	Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. <i>Blood</i> , 2005 , 105, 49-53	2.2	349
148	Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. <i>Blood</i> , 2005 , 105, 3420-7	2.2	108
147	Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. <i>Leukemia Research</i> , 2005 , 29, 1253-7	2.7	90
146	Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2005 , 35, 965-70	4.4	48
145	Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. <i>Chemico-Biological Interactions</i> , 2005 , 153-154, 187-95	5	46
144	Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. <i>Cancer</i> , 2005 , 104, 1442-52	6.4	364
143	Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9234-42	2.2	199
142	Phase II trial of oral aminopterin for adults and children with refractory acute leukemia. <i>Clinical Cancer Research</i> , 2005 , 11, 8089-96	12.9	19
141	Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. <i>Clinical Cancer Research</i> , 2005 , 11, 4176-81	12.9	118
140	Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 482-93 ^{2,2}		106
139	Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5728-38	2.2	122
138	Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 2711-8	4	10

137	Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5705-17	2.2	272
136	Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).. <i>Blood</i> , 2005 , 106, 165-165	2.2	2
135	Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.. <i>Blood</i> , 2005 , 106, 1833-1833	2.2	5
134	Response Rates in Patients with Acute Myeloid Leukemia (AML), Treated with Azacitidine, Using WHO and International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS).. <i>Blood</i> , 2005 , 106, 1848-1848	2.2	4
133	Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.. <i>Blood</i> , 2005 , 106, 2022-2022	2.2	1
132	Treatment Failure Is Strongly Predicted by P-Glycoprotein (Pgp) Function but Not by Multidrug Resistance Protein (MRP-1), Breast Cancer Resistance Protein (BCRP) or Lung Resistance Protein (LRP) in Acute Myeloid Leukemia (AML) Patients 60 Years and Older Receiving Intensive Chemotherapy (C11-C2-0700/0710).. <i>Blood</i> , 2005 , 106, 2219-2219	2.2	1
131	Azacitidine Prolongs Survival and Time to AML Transformation in High-Risk Myelodysplastic Syndrome (MDS) Patients \geq 65 Years of Age.. <i>Blood</i> , 2005 , 106, 2524-2524	2.2	2
130	A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients \leq 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808.. <i>Blood</i> , 2005 , 106, 407-407	2.2	17
129	Alemtuzumab (Campath 1-H) Exposure Correlates with Risk of Chronic Graft vs Host Disease and CMV Viremia after Allogeneic Transplantation.. <i>Blood</i> , 2005 , 106, 1818-1818	2.2	
128	Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1200-201	2.2	134
127	Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon- β : A Cancer and Leukemia Group B study 2004 , 25, 143		1
126	Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4816-22	2.2	41
125	Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13;q22) or t(16;16)(p13;q22): results from CALGB 8461. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1087-94	2.2	166
124	Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2410-8	2.2	89
123	A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 54, 553-61	3.5	4
122	Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. <i>British Journal of Haematology</i> , 2004 , 124, 275-88	4.5	57
121	RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. <i>Genes Chromosomes and Cancer</i> , 2004 , 39, 217-23	5	55
120	Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. <i>Cancer</i> , 2004 , 100, 1438-48	6.4	86

119	Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. <i>Cancer</i> , 2004 , 101, 1420-7	6.4	30
118	Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation. <i>Leukemia Research</i> , 2004 , 28, 537-40	2.7	4
117	Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. <i>Lancet, The</i> , 2004 , 363, 535-6	40	123
116	Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. <i>Blood</i> , 2004 , 103, 4373-4	2.2	6
115	Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. <i>Blood</i> , 2004 , 104, 3520-6	2.2	79
114	Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. <i>Blood</i> , 2004 , 103, 4036-42	2.2	82
113	Therapy-related myeloid leukemia: stochastic or idiosyncratic?. <i>Blood</i> , 2004 , 104, 602-603	2.2	1
112	Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).. <i>Blood</i> , 2004 , 104, 1145-1145	2.2	4
111	Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.. <i>Blood</i> , 2004 , 104, 2321-2321	2.2	1
110	The Histone Deacetylase Inhibitor Depsipeptide Has Differential Activity in Specific Cytogenetic Subsets of Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2004 , 104, 264-264	2.2	9
109	A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902.. <i>Blood</i> , 2004 , 104, 873-873	2.2	4
108	Prospective Study of Immunomodulation with GM-CSF, IL-2, and Rituximab Following Autologous Stem Cell Transplant (SCT) in Patients with Relapsed Lymphomas.. <i>Blood</i> , 2004 , 104, 918-918	2.2	2
107	Sequential Phase II Studies of Flavopiridol by 72-Hour Continuous Infusion and 1-Hour Intravenous Bolus for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from CALGB Study 19805.. <i>Blood</i> , 2004 , 104, 3485-3485	2.2	
106	Is Family History of Breast Cancer Associated with Therapy-Related Myelodysplastic Syndrome and Therapy-Related Leukemia? .. <i>Blood</i> , 2004 , 104, 2018-2018	2.2	
105	Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. <i>New England Journal of Medicine</i> , 2003 , 348, 994-1004	59.2	2797
104	Progress and challenges in the therapy of adult acute lymphoblastic leukemia. <i>Current Opinion in Hematology</i> , 2003 , 10, 284-9	3.3	9
103	Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia. <i>Blood</i> , 2003 , 102, 7-16	2.2	47
102	BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. <i>Blood</i> , 2003 , 102, 1613-8	2.2	202

101	Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2003 , 102, 2309; author reply 2309-10	2.2	2
100	Polymorphisms in the MLL breakpoint cluster region (BCR). <i>Human Genetics</i> , 2003 , 113, 80-91	6.3	14
99	Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. <i>Cancer</i> , 2003 , 97, 1471-80	6.4	54
98	A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. <i>Leukemia</i> , 2003 , 17, 323-7	10.7	44
97	Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?. <i>Leukemia</i> , 2003 , 17, 488-91	10.7	9
96	Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. <i>Leukemia</i> , 2003 , 17, 499-514	10.7	66
95	Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). <i>Leukemia</i> , 2003 , 17, 691-9	10.7	31
94	Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. <i>Leukemia Research</i> , 2003 , 27, 1091-6	2.7	20
93	Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). <i>Blood</i> , 2003 , 101, 6-14	2.2	486
92	Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4642-9	2.2	2107
91	Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. <i>Blood</i> , 2003 , 102, 43-52	2.2	541
90	Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. <i>Leukemia and Lymphoma</i> , 2003 , 44, 39-48	1.9	14
89	Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2138-46	2.2	153
88	Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3878-84	2.2	143
87	t(1;3)(p36;p21) is a recurring therapy-related translocation. <i>Genes Chromosomes and Cancer</i> , 2002 , 34, 186-92	5	11
86	Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 37-45	3.5	53
85	Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). <i>Leukemia</i> , 2002 , 16, 1627-36	10.7	195
84	Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). <i>Blood</i> , 2002 , 100, 4325-36	2.2	1287

83	Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2441-52	2.2	325
82	Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 3070-5	11.5	87
81	Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461 2002 , 21, 1041		6
80	Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 14925-30	11.5	123
79	Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. <i>Blood</i> , 2002 , 99, 3530-9	2.2	986
78	Acute lymphoblastic leukaemia: diagnosis and classification. <i>Best Practice and Research in Clinical Haematology</i> , 2002 , 15, 597-621	4.2	38
77	Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2429-40	2.2	1478
76	Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. <i>Blood</i> , 2002 , 100, 1224-1232	2.2	308
75	Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. <i>Blood</i> , 2002 , 100, 1224-32	2.2	84
74	Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. <i>Clinical Cancer Research</i> , 2002 , 8, 2812-9	12.9	31
73	Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. <i>International Journal of Oncology</i> , 2002 , 21, 1041-51	1	13
72	Rapid presumptive diagnosis of hantavirus cardiopulmonary syndrome by peripheral blood smear review. <i>American Journal of Clinical Pathology</i> , 2001 , 116, 665-72	1.9	94
71	Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). <i>Genomics</i> , 2001 , 71, 235-45	4.3	81
70	Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2001 , 41, 297-307	1.9	12
69	Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3611-21	2.2	121
68	Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3244-54	2.2	733
67	Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2482-92	2.2	86
66	Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethylol @ (Amifostine). <i>Leukemia Research</i> , 2000 , 24, 671-80	2.7	4

65	Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1301-8	2.2	49
64	Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2000 , 343, 1750-7	59.2	840
63	Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map. <i>Genomics</i> , 2000 , 67, 28-39	4.3	37
62	Prevalence of the Inactivating 609C→T Polymorphism in the NAD(P)H:Quinone Oxidoreductase (NQO1) Gene in Patients With Primary and Therapy-Related Myeloid Leukemia. <i>Blood</i> , 1999 , 94, 803-807 ^{2.2}		231
61	Prevalence of the Inactivating 609C→T Polymorphism in the NAD(P)H:Quinone Oxidoreductase (NQO1) Gene in Patients With Primary and Therapy-Related Myeloid Leukemia. <i>Blood</i> , 1999 , 94, 803-807 ^{2.2}		9
60	High-energy total body irradiation as preparation for bone marrow transplantation in leukemia patients: treatment technique and related complications. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998 , 40, 391-6	4	28
59	Myeloid Leukemia After Cytotoxic Therapy and Other Hematotoxins. <i>Hematology</i> , 1998 , 3, 397-400	2.2	
58	CBFA2(AML1) Translocations With Novel Partner Chromosomes in Myeloid Leukemias: Association With Prior Therapy. <i>Blood</i> , 1998 , 92, 2879-2885	2.2	101
57	Metastatic adenocarcinoma arising in a congenital foregut cyst of the esophagus: a case report with review of the literature. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998 , 21, 64-6	2.7	47
56	dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53. <i>Genes Chromosomes and Cancer</i> , 1997 , 20, 282-91	5	51
55	Long-term follow-up of cancer and leukemia group B studies in acute myeloid leukemia. <i>Cancer</i> , 1997 , 80, 2210-2214	6.4	17
54	Long-term follow-up of Cancer and Leukemia Group B studies in acute myeloid leukemia. <i>Cancer</i> , 1997 , 80, 2210-4	6.4	5
53	Therapy-related myeloid leukemia. <i>Hematology/Oncology Clinics of North America</i> , 1996 , 10, 293-320	3.1	126
52	Acute myelomonocytic leukemia with abnormal eosinophils presenting as an ovarian mass: a report of two cases and a review of the literature. <i>Gynecologic Oncology</i> , 1995 , 56, 307-11	4.9	23
51	Reimmunization after allogeneic bone marrow transplantation. <i>American Journal of Medicine</i> , 1995 , 98, 389-98	2.4	26
50	Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 36, 204-10	3.5	1
49	Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. <i>Leukemia and Lymphoma</i> , 1994 , 14, 257-62 ^{1.9}		20
48	Acute leukemia in adults: recent developments in diagnosis and treatment. <i>Ca-A Cancer Journal for Clinicians</i> , 1994 , 44, 326-52	220.7	21

47	Effects of rhGM-CSF on myeloid clonogenic cells in acute myelogenous leukemia patients. <i>Leukemia and Lymphoma</i> , 1993 , 10, 183-6	1.9	2
46	Listeriosis after 2-chlorodeoxyadenosine treatment. <i>New England Journal of Medicine</i> , 1993 , 328, 813-4	59.2	13
45	Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. <i>New England Journal of Medicine</i> , 1993 , 329, 909-14	59.2	444
44	Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia. <i>American Journal of Hematology</i> , 1993 , 42, 147-57	7.1	11
43	Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia. <i>American Journal of Hematology</i> , 1993 , 42, 359-66	7.1	9
42	Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study. <i>American Journal of Hematology</i> , 1993 , 43, 286-90	7.1	22
41	Acute myeloid leukaemia following interferon-alfa treatment of hairy cell leukaemia. <i>British Journal of Haematology</i> , 1993 , 83, 519-20	4.5	17
40	A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. <i>Leukemia and Lymphoma</i> , 1992 , 8, 229-33	1.9	40
39	c-myc and c-myb expression in acute myelogenous leukemia. <i>Leukemia Research</i> , 1992 , 16, 1003-11	2.7	26
38	The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study. <i>British Journal of Haematology</i> , 1992 , 82, 337-46	4.5	14
37	Cell cycle and clinical characteristics of patients with acute myeloid leukemia and myelodysplasia whose biopsies are reactive with anti-factor VIII antibody. A Leukemia Intergroup Study. <i>Leukemia Research</i> , 1991 , 15, 51-7	2.7	3
36	Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: a review of three consecutive trials of the treatment of poor prognosis patients. <i>Leukemia Research</i> , 1991 , 15, 773-80	2.7	28
35	Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukemia. <i>British Journal of Haematology</i> , 1991 , 79, 33-9	4.5	17
34	The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure. <i>British Journal of Haematology</i> , 1991 , 79, 390-7	4.5	21
33	Neurocysticercosis Coincident with Acute Myeloid Leukemia: A Case Report. <i>Leukemia and Lymphoma</i> , 1991 , 4, 145-8	1.9	1
32	Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). <i>Genes Chromosomes and Cancer</i> , 1990 , 2, 147-58	5	97
31	Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia. <i>Cancer</i> , 1990 , 65, 2619-23	3.4	8
30	Deletions of interferon genes in acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 1990 , 322, 77-82	59.2	187

29	Relapse of Hodgkin's Disease After 14 Years of Complete Remission. <i>Leukemia and Lymphoma</i> , 1990 , 3, 223-6	1.9	4
28	Methyl transferase activity in secondary leukemia. <i>Basic Life Sciences</i> , 1990 , 53, 277-89		
27	Chromosomal sensitivity of lymphocytes from individuals with therapy-related acute nonlymphocytic leukemia. <i>Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology</i> , 1989 , 216, 119-26		12
26	Hypersensitivity reaction to high-dose cytarabine. <i>British Journal of Haematology</i> , 1989 , 73, 274-5	4.5	15
25	Der(5)t(5;7)(q11.2;p11.2): a new recurring abnormality in malignant myeloid disorders. <i>Cancer Genetics and Cytogenetics</i> , 1989 , 37, 1-8		12
24	Acute leukemia occurring after radiotherapy and chemotherapy with a nitrosourea, PCNU. <i>Investigational New Drugs</i> , 1988 , 6, 121-4	4.3	2
23	Disseminated cutaneous and peritoneal hyalohyphomycosis caused by <i>Fusarium</i> species: three cases and review of the literature. <i>Mycopathologia</i> , 1988 , 101, 105-11	2.9	41
22	Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy. <i>American Journal of Medicine</i> , 1988 , 84, 233-9	2.4	111
21	A recurring chromosome rearrangement, dic(16;22), in acute nonlymphocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1988 , 35, 143-50		2
20	Associations between morphology, karyotype, and clinical features in myeloid leukemias. <i>Human Pathology</i> , 1987 , 18, 211-25	3.7	121
19	High-performance liquid chromatographic assay for mitoxantrone in plasma using electrochemical detection. <i>Biomedical Applications</i> , 1987 , 420, 81-8		22
18	Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 1986 , 18, 257-60	3.5	1
17	New high-performance liquid chromatographic assay for plasma doxorubicin. <i>Biomedical Applications</i> , 1985 , 337, 194-200		18
16	The utility of ultrasound in the diagnosis of wandering abdominal viscera. <i>Journal of Clinical Ultrasound</i> , 1985 , 13, 275-7	1	5
15	Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. <i>Cancer</i> , 1985 , 56, 443-9	6.4	58
14	High-dose Ara-C plus VM-26 in adult acute lymphoblastic leukemia. <i>European Journal of Cancer & Clinical Oncology</i> , 1985 , 21, 1261-3		3
13	Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: relationship to response to remission induction therapy. <i>European Journal of Cancer & Clinical Oncology</i> , 1985 , 21, 563-71		13
12	Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 1984 , 12, 125-30	3.5	46

11	Inhibition of DNA synthesis by cytosine arabinoside: relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease. <i>European Journal of Cancer & Clinical Oncology</i> , 1984 , 20, 1061-8		10
10	Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. <i>American Journal of Medicine</i> , 1984 , 76, 827-41	2.4	343
9	The DNA synthetic response of normal and abnormal human lymphocytes to mevalonic acid: the role of granulocytes as a helper population. <i>Journal of Allergy and Clinical Immunology</i> , 1984 , 74, 280-90	11.5	
8	A morphologic and cytochemical study of acute myelomonocytic leukemia with abnormal marrow eosinophils associated with inv(16)(p13q22). <i>American Journal of Clinical Pathology</i> , 1984 , 81, 733-41	1.9	55
7	The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: a 12-year study (1970-1982). <i>Cancer Genetics and Cytogenetics</i> , 1983 , 10, 219-36		91
6	Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. <i>New England Journal of Medicine</i> , 1983 , 309, 630-6	59.2	438
5	Neutrophil-assisted DNA synthesis by human lymphocytes in response to mevalonic acid; enhancement by cytochalasin B. <i>Cellular Immunology</i> , 1983 , 81, 357-72	4.4	
4	Response to 5-azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findings. <i>Cancer</i> , 1982 , 49, 2222-5	6.4	13
3	Chromosome changes in hematologic malignancies. <i>Ca-A Cancer Journal for Clinicians</i> , 1981 , 31, 222-38	220.7	6
2	Acute Myeloid Leukemia in Adults: Remission Induction Therapy 268-277		
1	Acute Myeloid Leukemia in Adults: Postremission Therapy 278-286		